Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
65 hedge funds and large institutions have $40.8M invested in Syros Pharmaceuticals, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 17 closing their positions.
7% less funds holding
Funds holding: 70 → 65 (-5)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
61% less capital invested
Capital invested by funds: $105M → $40.8M (-$64.4M)
90% less call options, than puts
Call options by funds: $281K | Put options by funds: $2.73M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BOCH
Blue Owl Capital Holdings
New York
|
+$629K |
| 2 |
EAM
Exome Asset Management
New York
|
+$501K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$292K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$178K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$177K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$12.9M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$2.21M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$2.19M |
| 4 |
Goldman Sachs
New York
|
-$1.35M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$756K |
SYRS Hedge Fund Activity: Q3 2024 in Review
65 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q3 2024, worth a combined $40.8M — down 61% from $105M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of SYRS and 12 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 11 added.
The largest buyer was Blue Owl Capital Holdings, adding an estimated $629K. The largest seller was Artal Group, exiting entirely with an estimated $12.9M sold.
- 65 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q3 2024, down from 70 in Q2 2024.
- Funds reported $40.8M of Syros Pharmaceuticals, Inc. Common Stock stock for Q3 2024, down 61% quarter-over-quarter.
- 12 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q3 2024 and 17 closed out, a net change of -5 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q3 2024 was Blue Owl Capital Holdings, an estimated $629K added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q3 2024 was Artal Group, an estimated $12.9M sold.
Based on aggregated 13F filings for Q3 2024.